Pulmonx Corporation (LUNG) Reports 75.8% Collateral Ventilation Conversion

Pulmonx (LUNG) reported 75.8% of patients converted from CV+ to CV− after AeriSeal treatment in the CONVERT Trial. 88.9% of evaluable patients achieved significant target-lobe volume reduction with Zephyr Valves. AeriSeal is under pivotal evaluation, with CONVERT II results needed for U.S. PMA application.

Original reporting
Published Nov 17, 2026, 12:10 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 17, 2026, 12:15 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Pulmonx Corporation (LUNG) Reports 75.8% Collateral Ventilation Conversion — source image
Decision brief

The 30-second read

$LUNGBullishMed
01

Why it matters

The reported conversion and target-lobe reduction rates strengthen the efficacy narrative for the treatment pathway and set expectations for upcoming six-month results tied to a potential U.S. PMA application for AeriSeal.

02

Market read

Traders can update probabilities for Zephyr pathway efficacy now and for AeriSeal’s PMA timeline as CONVERT II six-month results approach.

03

What to watch

Durability and safety details are not provided here; traders may wait for full endpoints, adverse event profile, and regulatory submission timing clarity before repricing risk.

Relevance 7/10Novelty 7/10Timing: today’s update on CONVERT trial efficacy percentages

Background

Pulmonx is evaluating AeriSeal (collateral ventilation conversion) and Zephyr valves in the CONVERT program, with CONVERT II planned to generate additional pivotal data.

Company-level read

Ticker impact

$LUNGBullishMedium confidence
Context

Pulmonx reports CONVERT trial results, with 75.8% converting after AeriSeal and 88.9% achieving target-lobe reduction with Zephyr valves at 45 days.

Expected impact

Likely upward bias as traders price improved clinical efficacy and potential future PMA progress for AeriSeal.

Evidence & confidence

The article provides specific, trial-level efficacy percentages and a stated regulatory pathway (six-month results supporting a U.S. PMA), which can drive biotech sentiment and expectations, though it is not an approval or filing yet.

Market effects

Reinforces investor appetite for endobronchial valve and collateral ventilation conversion approaches in COPD/air-trapping, potentially lifting sentiment across similar interventional pulmonology names.

Limited direct regional impact; primarily affects US-listed small-cap biotech sentiment.

Moderate, as trial efficacy data can influence global expectations for device-based COPD interventions, but no cross-border regulatory decision is reported.

Counterpoint

AeriSeal remains under pivotal evaluation, so the market may discount the conversion headline until CONVERT II six-month results are available.

Key entities

  • Pulmonx Corporation

    Reports CONVERT trial efficacy: 75.8% conversion after AeriSeal and 88.9% target-lobe reduction with Zephyr valves at 45 days, persisting through 12 months.

  • AeriSeal

    Collateral ventilation conversion treatment evaluated in CONVERT; pivotal evaluation continues with CONVERT II six-month results needed for PMA support.

  • Zephyr valves

    Endobronchial valves evaluated after AeriSeal in CONVERT; 88.9% achieved clinically significant target-lobe volume reduction at 45 days.

  • CONVERT Trial

    Clinical evidence source for the reported conversion and valve efficacy outcomes.

Related articles

$LUNGMed

Pulmonx Corporation: Pulmonx Announces Publication of CONVERT Trial Results for AeriSeal System

Pulmonx Corporation (Nasdaq: LUNG) announced the publication of CONVERT Trial results for its AeriSeal System, showing 75.8% of patients with severe emphysema and collateral ventilation had successful treatment. The study suggests the system could enable subsequent treatment with Zephyr Valves, improving lung function and quality of life. Pulmonx is now conducting the CONVERT II Pivotal Trial to support a U.S. FDA Premarket Approval application for the AeriSeal System.

$LUNGMed

Pulmonx reports trial results for emphysema treatment system

Pulmonx (LUNG) reported CONVERT Trial results for its AeriSeal System in severe emphysema patients, showing 75.8% success in converting collateral ventilation status. Treated patients achieved 88.9% target lobe volume reduction at 45 days, with improvements in lung function and quality of life. The company is enrolling patients in the CONVERT II Pivotal Trial for U.S. FDA approval.

$GMABHighAI 8/10

Biotech Stocks Rise: GMAB Surges, LUNG And AXGN Gain Over 30%

Genmab (GMAB) shares rose 33% after reporting positive Phase 3 results for its cancer drug. Pulmonx (LUNG) and Axogen (AXGN) shares gained over 30% on strong quarterly results. OrthoPediatrics (KIDS) and Replimune (REPL) also reported improved financials, driving their stock prices up. Specific financial data and guidance were provided by each company.

$LUNGHigh

Pulmonx (LUNG) Q3 2026 Earnings Call Transcript

Pulmonx (LUNG) reported Q3 2026 revenue of $22.8M, up 6% YoY, marking a return to growth. U.S. revenue rose 7% to $14.9M, while international revenue increased 5% to $7.9M. The company reduced adjusted EBITDA loss by 60% to $3.5M and expects full-year revenue of $90M-$92M. Gross margin improved to 76%, and operating expenses decreased 18% YoY to $24.9M. Pulmonx aims to expand its market through AeriSeal and restart commercial activity in China.